Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited filed its Monthly Return for the period ended 31 March 2026, confirming a stable capital structure with no share movements during the month.

Key disclosures

1. Authorised / registered share capital • Total authorised shares remained at 1.63 billion, comprising: – H shares: 219.90 million, par value RMB 1 each. – A shares: 1.41 billion, par value RMB 1 each. • No increases or reductions were recorded in either class of shares during March 2026.

2. Issued share capital and treasury shares • Issued H shares stood unchanged at 219.90 million, with zero treasury shares. • Issued A shares also remained unchanged at 1.41 billion, with zero treasury shares. • Consequently, the company’s total issued share count stayed at 1.63 billion.

3. Public-float compliance • The company confirmed that its H-share public float exceeded the regulatory minimum of 5% of the relevant class’s issued shares, satisfying Main Board Rule 13.32D(1).

4. Capital-raising instruments • The return reported no outstanding share options, warrants, convertibles, or other agreements that could dilute the current share base. • No share repurchases, cancellations, redemptions, or treasury share transactions occurred during the month.

5. Regulatory compliance • The Company Secretary affirmed full compliance with listing rules and all relevant legal and regulatory requirements for the reporting period.

The March 2026 filing underscores Baiyunshan Pharma’s unchanged equity structure and continued adherence to Hong Kong listing regulations.